Does Medication Sampling Improve Compliance with Brief Advice? Results from a Pragmatic Randomized Clinical Trial.
Journal
Journal of smoking cessation
ISSN: 1834-2612
Titre abrégé: J Smok Cessat
Pays: England
ID NLM: 101478447
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
8
4
2021
pubmed:
9
4
2021
medline:
9
4
2021
Statut:
ppublish
Résumé
The 5As model is a standard component of most guidelines for tobacco treatment. Unfortunately, provider adherence to this model is modest. Providing physicians with adjunctive tools to adhere to 5As guidelines may serve as a catalyst for brief advice delivery. This was a secondary data analysis of a cluster randomized clinical trial assessing the uptake and impact of free nicotine replacement therapy (NRT) sampling versus standard care in primary care. Patients reported receipt of separate elements of the 5As model, assessed one month following a baseline visit. Analyses compared patients who recalled receipt of brief advice among those who received NRT vs. standard care. Additional analyses examined demographic predictors of receiving brief advice. Medication sampling did not improve compliance with ask, advise, or assess. Receipt of "assistance" was significantly higher among NRT recipients (70%) ( Provision of NRT sampling increased provider compliance with some elements of the brief advice model, thus enhancing the impact of cessation advice within primary care. This trial is registered with ClinicalTrials.gov NCT02096029.
Identifiants
pubmed: 33828613
doi: 10.1155/2021/6638872
pmc: PMC8023690
mid: NIHMS1686941
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02096029']
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIDA NIH HHS
ID : K23 DA045766
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA021619
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001450
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Déclaration de conflit d'intérêts
Conflicts of Interest Drs. Carpenter and Toll have received consulting honoraria from Pfizer. Dr. Toll has additionally served as a paid expert witness in litigation filed against the tobacco industry. All other authors declare no conflict of interest.
Références
Addiction. 2020 Jul;115(7):1358-1367
pubmed: 31916303
J Eval Clin Pract. 2008 Aug;14(4):537-44
pubmed: 18462288
Cochrane Database Syst Rev. 2013 May 31;(5):CD009329
pubmed: 23728690
JAMA Netw Open. 2019 May 3;2(5):e194585
pubmed: 31125108
JAMA Intern Med. 2015 Sep;175(9):1509-16
pubmed: 26076313
Nicotine Tob Res. 2010 Jul;12(7):724-33
pubmed: 20507899
Am J Prev Med. 2008 May;34(5):404-12
pubmed: 18407007
N Engl J Med. 2011 Sep 29;365(13):1222-31
pubmed: 21991895
Am Fam Physician. 2006 Jul 15;74(2):262-71
pubmed: 16883923
Tob Induc Dis. 2017 Nov 2;15:41
pubmed: 29142531
J Thorac Oncol. 2013 May;8(5):543-8
pubmed: 23529191
Am J Prev Med. 2008 Aug;35(2):158-76
pubmed: 18617085
Contemp Clin Trials. 2018 Sep;72:1-7
pubmed: 30010086
J Addict Dis. 2017 Jan-Mar;36(1):53-59
pubmed: 26566876
N Engl J Med. 2013 Jan 24;368(4):341-50
pubmed: 23343063
BMC Public Health. 2016 Feb 11;16:141
pubmed: 26868930